These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25634459)

  • 21. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma.
    Berger W; Gupta N; McAlary M; Fowler-Taylor A
    Ann Allergy Asthma Immunol; 2003 Aug; 91(2):182-8. PubMed ID: 12952113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma.
    Ohta K; Miyamoto T; Amagasaki T; Yamamoto M;
    Respirology; 2009 Nov; 14(8):1156-65. PubMed ID: 19909462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monitoring free serum IgE in severe asthma patients treated with omalizumab.
    Korn S; Haasler I; Fliedner F; Becher G; Strohner P; Staatz A; Taube C; Buhl R
    Respir Med; 2012 Nov; 106(11):1494-500. PubMed ID: 22884459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
    Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
    Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasmapheresis prior to omalizumab administration in a 15-year-old boy with severe asthma and very high IgE levels: sustained effect over 2 years.
    Kerzel S; Zemlin M; Rogosch T; Ollert M; Renz H; Klaus G; Maier RF
    Klin Padiatr; 2011 Nov; 223(6):356-9. PubMed ID: 22012605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma.
    Hochhaus G; Brookman L; Fox H; Johnson C; Matthews J; Ren S; Deniz Y
    Curr Med Res Opin; 2003; 19(6):491-8. PubMed ID: 14594521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
    Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
    J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Omalizumab: new drug. Asthma: too many unknowns for an anti-IgE.
    Prescrire Int; 2007 Oct; 16(91):179-82. PubMed ID: 17926440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
    Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
    Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modeling the effects of omalizumab over 5 years among patients with moderate-to-severe persistent allergic asthma.
    Grossman HL; Schlender A; Alperin P; Stanley EL; Zhang J
    Curr Med Res Opin; 2010 Dec; 26(12):2779-93. PubMed ID: 21050061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduction of the total IgE level by omalizumab in children and adolescents.
    Steiss JO; Strohner P; Zimmer KP; Lindemann H
    J Asthma; 2008 Apr; 45(3):233-6. PubMed ID: 18415832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Omalizumab protects against allergen- induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma.
    Zielen S; Lieb A; De La Motte S; Wagner F; de Monchy J; Fuhr R; Munzu C; Koehne-Voss S; Rivière GJ; Kaiser G; Erpenbeck VJ
    Int Arch Allergy Immunol; 2013; 160(1):102-10. PubMed ID: 22948442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Omalizumab therapy in severe asthma: experience from the Spanish registry--some new approaches.
    Vennera Mdel C; Pérez De Llano L; Bardagí S; Ausin P; Sanjuas C; González H; Gullón JA; Martínez-Moragón E; Carretero JA; Vera E; Medina JF; Alvarez FJ; Entrenas LM; Padilla A; Irigaray R; Picado C;
    J Asthma; 2012 May; 49(4):416-22. PubMed ID: 22443408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey.
    Deschildre A; Marguet C; Salleron J; Pin I; Rittié JL; Derelle J; Taam RA; Fayon M; Brouard J; Dubus JC; Siret D; Weiss L; Pouessel G; Beghin L; Just J
    Eur Respir J; 2013 Nov; 42(5):1224-33. PubMed ID: 23520319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal changes in asthma control with omalizumab: 2-year interim data from the EXCELS Study.
    Eisner MD; Zazzali JL; Miller MK; Bradley MS; Schatz M
    J Asthma; 2012 Aug; 49(6):642-8. PubMed ID: 22793527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma.
    Noga O; Hanf G; Brachmann I; Klucken AC; Kleine-Tebbe J; Rosseau S; Kunkel G; Suttorp N; Seybold J
    J Allergy Clin Immunol; 2006 Jun; 117(6):1493-9. PubMed ID: 16751018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between consistent omalizumab treatment and asthma control.
    Lafeuille MH; Gravel J; Zhang J; Gorsh B; Figliomeni M; Lefebvre P
    J Allergy Clin Immunol Pract; 2013 Jan; 1(1):51-7. PubMed ID: 24229822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Profile of patients treated with omalizumab in routine clinical practice in Spain.
    Ancochea J; Chivato T; Casan P; Picado C; Herráez L; Casafont J
    Allergol Immunopathol (Madr); 2014; 42(2):102-8. PubMed ID: 23267505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma.
    Kulus M; Hébert J; Garcia E; Fowler Taylor A; Fernandez Vidaurre C; Blogg M
    Curr Med Res Opin; 2010 Jun; 26(6):1285-93. PubMed ID: 20377320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
    Holgate ST; Djukanović R; Casale T; Bousquet J
    Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.